Among the most distinctive contributions of Russian biomedical research to the global peptide research toolkit are two synthetic heptapeptides with complementary neuropharmacological profiles: Selank 11mg and Semax 11mg. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, these peptides have accumulated substantial preclinical research literature and achieved registered pharmaceutical status in Russia.
Origins: From Tuftsin to Selank, and From ACTH to Semax
Selank (CAS 129954-34-3, MW 751.86 g/mol) was designed as an improved version of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from IgG with well-characterised neuromodulatory properties. The Pro-Gly-Pro C-terminal extension significantly improves metabolic stability while extending biological activity compared to the parent peptide. Semax (CAS 80714-61-0, MW 813.96 g/mol) is an analogue of the ACTH(4-7) fragment, the smallest unit of ACTH known to exert neurotrophic activity. By removing the steroidogenic portions of ACTH while retaining the neurotrophically relevant segment, researchers created a compound with potent BDNF-upregulating and neuroprotective properties without adrenocortical effects.
Shared and Distinct Mechanisms of Action
Despite different origins, Selank and Semax converge on overlapping neurobiological mechanisms that make them a compelling comparative research pair. Both compounds increase BDNF mRNA and protein levels in rodent hippocampus, though with distinct regional and temporal patterns enabling mechanistic dissection. Selank-specific pathways include enhanced GABAergic neurotransmission (anxiolytic-like effects via GABA-A receptor sensitivity modulation distinct from benzodiazepine mechanisms), serotonin turnover effects, and potential inhibition of enkephalin-degrading enzymes. Semax-specific pathways include particularly strong neuroprotection data in ischaemia models (reduced cytokine production in neural tissue, antioxidant effects) and melanocortin system interaction through ACTH-related receptor binding.
Research Design Considerations
Both peptides have short plasma half-lives due to peptidase activity, reflected in the 11mg vial sizes providing experimental flexibility. Intranasal delivery routes have been extensively studied for CNS delivery while bypassing first-pass metabolism. Comparative studies using both Selank and Semax allow researchers to probe the relative contributions of GABAergic modulation vs melanocortin/BDNF mechanisms to cognitive and anxiety-related phenotypes. Researchers studying the metabolic-cognitive interface may also find 5-Amino-1MQ 10mg relevant for its NAD+/NNMT-related neurological research implications.
Applications in Modern Neuropharmacology Research
The accessibility of well-characterised peptides like Selank and Semax opens opportunities for researchers studying GABAergic system pharmacology without benzodiazepine receptor complications; BDNF-dependent synaptic plasticity mechanisms; neuroprotective pathways in ischaemia models; and the interface between immune modulation and neurological biology. The 11mg format provides sufficient material for comprehensive experimental designs including dose-response characterisation and multi-timepoint mechanistic studies. For broader cognitive biology context, researchers may also investigate NAD+ 500mg for the metabolic-neurological axis.
All compounds are for laboratory research use only. Not for human or veterinary use.
